Sofinnova Partners raised a whopping €1.2 billion (US$1.26 billion) over the past year to invest in life sciences companies ranging from incubation to later-stage growth, and spanning biotech, med tech, industrial biotech and digital medicine.
Sofinnova Partners raised a whopping €1.2 billion (US$1.26 billion) over the past year to invest in life sciences companies ranging from incubation to later-stage growth, and spanning biotech, med tech, industrial biotech and digital medicine.
Precision Neuroscience Inc. recently partnered with Beth Israel Deaconess Medical Center to test its brain computer interface, the Layer 7 Cortical Interface, during craniotomy procedures.
Royal Philips NV recently secured EU MDR certification for the remote scanning capabilities on its Radiology Operations Command Center Console. The solution allows radiologists to remotely assist technologists in real-time by controlling scans to acquire images needed for improved diagnostic confidence and patient outcomes.
There is no doubt this year started with a boom for European med-tech companies. Public markets opened in the U.S. and cross-border investors are deploying capital. With many companies looking to conduct clinical trials, raising funds and bringing their devices to the market, 2025 is expected to be prosperous, mitigating the difficulties of the previous two to three years.
Scientists at the University of Aberdeen developed a new scanner that distinguishes breast tumor material from healthy tissue more accurately than current magnetic resonance imaging (MRI) methods.
Organox Ltd. raised $142 million in financing to accelerate the growth of its Metra platform that preserves and transport livers for transplantation. The funds will allow the company to strengthen its ability to support current customers, expand its customer base and enter new markets such as Canada and Australia, where it earned regulatory approvals within the last year, Steve Deitsch, CFO of Organox, told BioWorld.
Berlin Heals Holding AG recently raised over CHF7 million (US$7.8 million) in a financing round for C-MIC, a small implantable device it believes can reverse heart failure.
Approxima Srl raised €7.3 million (US$7.65 million) in the first close of its series A financing round for its tricuspid valve repair system which is based on reshaping the right ventricle.
